{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:11:42Z","timestamp":1793913102800,"version":"4.8.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA168878"],"award-info":[{"award-number":["U01 CA168878"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA151022"],"award-info":[{"award-number":["T32 CA151022"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001227","name":"T.J. Martell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001227","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCSF Loglio collective"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>IDH-mutant diffuse gliomas are heterogeneous, and improved methods for optimal patient therapeutic stratification are needed. PI3K\/AKT\/mTOR signaling activity can drive disease progression and potential therapeutic inhibitors of the pathway are available. Yet, the prevalence of PI3K\/AKT\/mTOR signaling pathway activity in IDH-mutant glioma is unclear and few robust strategies to assess activity in clinical samples exist.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PI3K\/AKT\/mTOR signaling pathway activity was evaluated in a retrospective cohort of 132 IDH-mutant diffuse glioma (91 astrocytoma and 41 oligodendroglioma, 1p\/19q-codeleted) through quantitative multiplex immunoprofiling using phospho-specific antibodies for PI3K\/AKT\/mTOR pathway members, PRAS40, RPS6, and 4EBP1, and tumor-specific anti-IDH1 R132H. Expression levels were correlated with genomic evaluation of pathway intrinsic genes and univariate and multivariate Cox proportional hazard regression models were used to evaluate the relationship with outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Tumor-specific expression of p-PRAS40, p-RPS6, and p-4EBP1 was common in IDH-mutant diffuse glioma and increased with CNS WHO grade from 2 to 3. Genomic analysis predicted pathway activity in 21.7% (13\/60) while protein evaluation identified active PI3K\/AKT\/mTOR signaling in 56.6% (34\/60). Comparison of expression in male versus female patients suggested sexual dimorphism. Of particular interest, when adjusting for clinical prognostic factors, the level of phosphorylation of RPS6 was strongly associated with PFS (P\u2005&amp;lt;\u2005.005). Phosphorylation levels of both PRAS40 and RPS6 showed an association with PFS in univariate analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study emphasizes the value of proteomic assessment of signaling pathway activity in tumors as a means to identify relevant oncogenic pathways and potentially as a biomarker for identifying aggressive disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noac064","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T20:11:22Z","timestamp":1647029482000},"page":"1471-1481","source":"Crossref","is-referenced-by-count":77,"title":["PI3K\/AKT\/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications"],"prefix":"10.1093","volume":"24","author":[{"given":"Esraa","family":"Mohamed","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunita","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anny","family":"Shai","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie W","family":"Taylor","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Neurology, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8054-7342","authenticated-orcid":false,"given":"Jennifer","family":"Clarke","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Neurology, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Hilz","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1983-4892","authenticated-orcid":false,"given":"Mitchel S","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F","family":"Costello","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9854-7404","authenticated-orcid":false,"given":"Annette M","family":"Molinaro","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna J","family":"Phillips","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco , San Francisco, California , USA"},{"name":"Division of Neuropathology, Department of Pathology, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"issue":"26","key":"2022090114005398800_CIT0001","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors","volume":"372","author":"Eckel-Passow","year":"2015","journal-title":"N Engl J Med."},{"issue":"26","key":"2022090114005398800_CIT0002","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Cancer Genome ARN, Brat DJ, Verhaak RG, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"2022090114005398800_CIT0003","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncol"},{"issue":"8","key":"2022090114005398800_CIT0004","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/neuonc\/nov031","article-title":"Toward precision medicine in glioblastoma: the promise and the challenges","volume":"17","author":"Prados","year":"2015","journal-title":"Neuro-Oncol"},{"key":"2022090114005398800_CIT0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/1078-0432.CCR-17-0963","article-title":"Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma","volume":"24","author":"Byron","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"2022090114005398800_CIT0006","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell."},{"issue":"6167","key":"2022090114005398800_CIT0007","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.1239947","article-title":"Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma","volume":"343","author":"Johnson","year":"2014","journal-title":"Science."},{"issue":"10","key":"2022090114005398800_CIT0008","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2004.07.193","article-title":"The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas","volume":"22","author":"Chakravarti","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"2022090114005398800_CIT0009","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","article-title":"A pan-cancer proteogenomic atlas of PI3K\/AKT\/mTOR pathway alterations","volume":"31","author":"Zhang","year":"2017","journal-title":"Cancer Cell."},{"issue":"7216","key":"2022090114005398800_CIT0010","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Cancer Genome Atlas Research Network","year":"2008","journal-title":"Nature"},{"issue":"2","key":"2022090114005398800_CIT0011","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-010-0297-3","article-title":"Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the children\u2019s oncology group","volume":"99","author":"Pollack","year":"2010","journal-title":"J Neurooncol."},{"issue":"12","key":"2022090114005398800_CIT0012","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/neuonc\/not132","article-title":"Activation of mTORC1\/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target","volume":"15","author":"H\u00fctt-Cabezas","year":"2013","journal-title":"Neuro-Oncol"},{"issue":"9","key":"2022090114005398800_CIT0013","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/nos140","article-title":"PTEN promoter methylation and activation of the PI3K\/Akt\/mTOR pathway in pediatric gliomas and influence on clinical outcome","volume":"14","author":"Mueller","year":"2012","journal-title":"Neuro-Oncol"},{"issue":"5848","key":"2022090114005398800_CIT0014","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science."},{"issue":"2","key":"2022090114005398800_CIT0015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell."},{"issue":"4","key":"2022090114005398800_CIT0016","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1750-3639.2004.tb00080.x","article-title":"Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas","volume":"14","author":"Mizoguchi","year":"2004","journal-title":"Brain Pathol Zurich Switz"},{"issue":"11","key":"2022090114005398800_CIT0017","first-page":"2742","article-title":"Analysis of the Phosphatidylinositol 3\u2032-kinase signaling pathway in glioblastoma patients in vivo","volume":"63","author":"Choe","year":"2003","journal-title":"Cancer Res."},{"issue":"8","key":"2022090114005398800_CIT0018","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-19-2808","article-title":"First-in-Human Phase I Study to evaluate the brain-penetrant PI3K\/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma","volume":"26","author":"Wen","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"2022090114005398800_CIT0019","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","article-title":"A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma","volume":"31","author":"Fan","year":"2017","journal-title":"Cancer Cell."},{"key":"2022090114005398800_CIT0020","doi-asserted-by":"crossref","first-page":"12700","DOI":"10.1038\/ncomms12700","article-title":"The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway","volume":"7","author":"Carbonneau","year":"2016","journal-title":"Nat Commun."},{"issue":"6","key":"2022090114005398800_CIT0021","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/1535-7163.MCT-11-0048","article-title":"Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib\u2014a phase II trial","volume":"10","author":"Hegi","year":"2011","journal-title":"Mol Cancer Ther."},{"issue":"16","key":"2022090114005398800_CIT0022","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/onc.2016.363","article-title":"mTORC1 and mTORC2 in cancer and the tumor microenvironment","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene."},{"issue":"1","key":"2022090114005398800_CIT0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1078-0432.CCR-17-0042","article-title":"Inhibiting 4EBP1 in glioblastoma","volume":"24","author":"Fan","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"2022090114005398800_CIT0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-2094-8-3","article-title":"Microglial MAC1 receptor and PI3K are essential in mediating \u03b2-amyloid peptide-induced microglial activation and subsequent neurotoxicity","volume":"8","author":"Zhang","year":"2011","journal-title":"J Neuroinflammation."},{"issue":"41","key":"2022090114005398800_CIT0025","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene."},{"key":"2022090114005398800_CIT0026","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41698-018-0067-9","article-title":"Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways","volume":"2","author":"Halani","year":"2018","journal-title":"npj Precis Oncol."},{"issue":"9","key":"2022090114005398800_CIT0027","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/1878-0261.12099","article-title":"Analysis of mutant allele fractions in driver genes in colorectal cancer \u2013 biological and clinical insights","volume":"11","author":"Dienstmann","year":"2017","journal-title":"Mol Oncol."},{"issue":"1","key":"2022090114005398800_CIT0028","doi-asserted-by":"crossref","first-page":"14.15.1","DOI":"10.1002\/0471142727.mb1415s102","article-title":"Basic image analysis and manipulation in ImageJ","volume":"102","author":"Hartig","year":"2013","journal-title":"Curr Protoc Mol Biol"},{"issue":"12","key":"2022090114005398800_CIT0029","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/s43018-021-00260-2","article-title":"ERK1\/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma","volume":"2","author":"Arrieta","year":"2021","journal-title":"Nat Cancer."},{"key":"2022090114005398800_CIT0030","volume-title":"An Introduction to Recursive Partitioning Using the RPART Routines","author":"Therneau","year":"1997"},{"issue":"17-18","key":"2022090114005398800_CIT0031","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/(SICI)1097-0258(19990915\/30)18:17\/18<2529::AID-SIM274>3.0.CO;2-5","article-title":"Assessment and comparison of prognostic classification schemes for survival data","volume":"18","author":"Graf","year":"1999","journal-title":"Stat Med."},{"key":"2022090114005398800_CIT0032","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/9780470567647.ch10","article-title":"Statistical resampling for large screening data analysis such as classical resampling Bootstrapping, Markov chain Monte Carlo, and statistical simulation and validation strategies.","volume-title":"Statistical Bioinformatics: A Guide for Life and Biomedical Science Researchers","author":"Molinaro","year":"2010"},{"issue":"15","key":"2022090114005398800_CIT0033","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92142","article-title":"Sexual dimorphism in glioma glycolysis underlies sex differences in survival","volume":"2","author":"Ippolito","year":"2017","journal-title":"JCI Insight."},{"issue":"3","key":"2022090114005398800_CIT0034","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/acel.12194","article-title":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","volume":"13","author":"Miller","year":"2014","journal-title":"Aging Cell."},{"issue":"1","key":"2022090114005398800_CIT0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/acel.12425","article-title":"Sex- and tissue-specific changes in mTOR signaling with age in C57BL\/6J mice","volume":"15","author":"Baar","year":"2016","journal-title":"Aging Cell."},{"issue":"3","key":"2022090114005398800_CIT0036","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1124\/jpet.105.090803","article-title":"Gender differences in cardioprotection against ischemia\/reperfusion injury in adult rat hearts: focus on Akt and protein kinase C signaling","volume":"315","author":"Bae","year":"2005","journal-title":"J Pharmacol Exp Ther."},{"issue":"6","key":"2022090114005398800_CIT0037","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00401-015-1438-8","article-title":"IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO","volume":"129","author":"Reuss","year":"2015","journal-title":"Acta Neuropathol (Berl)"},{"issue":"4","key":"2022090114005398800_CIT0038","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00401-015-1398-z","article-title":"IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II\u2013III diffuse gliomas","volume":"129","author":"Olar","year":"2015","journal-title":"Acta Neuropathol (Berl)"},{"issue":"5","key":"2022090114005398800_CIT0039","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/noz016","article-title":"Accelerated progression of IDH mutant glioma after first recurrence","volume":"21","author":"Miller","year":"2019","journal-title":"Neuro-Oncol"},{"issue":"1","key":"2022090114005398800_CIT0040","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1371\/journal.pmed.0050008","article-title":"Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma","volume":"5","author":"Cloughesy","year":"2008","journal-title":"PLoS Med."},{"issue":"1","key":"2022090114005398800_CIT0041","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-009-0004-4","article-title":"Activation of PI3K\/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival","volume":"97","author":"McBride","year":"2010","journal-title":"J Neurooncol."},{"issue":"23","key":"2022090114005398800_CIT0042","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1002\/cncr.30909","article-title":"Probing the phosphatidylinositol 3-kinase\/mammalian target of rapamycin pathway in gliomas: a phase 2 study of everolimus for recurrent adult low-grade gliomas","volume":"123","author":"Wahl","year":"2017","journal-title":"Cancer."},{"issue":"7274","key":"2022090114005398800_CIT0043","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature."},{"issue":"1","key":"2022090114005398800_CIT0044","doi-asserted-by":"crossref","first-page":"vdaa149","DOI":"10.1093\/noajnl\/vdaa149","article-title":"The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling","volume":"3","author":"Yamashita","year":"2021","journal-title":"Neuro-Oncol Adv"},{"issue":"28","key":"2022090114005398800_CIT0045","doi-asserted-by":"crossref","first-page":"14662","DOI":"10.1074\/jbc.M115.694331","article-title":"MicroRNA-214 reduces insulin-like growth factor-1 (IGF-1) receptor expression and downstream mTORC1 signaling in renal carcinoma cells*","volume":"291","author":"Das","year":"2016","journal-title":"J Biol Chem."},{"issue":"16","key":"2022090114005398800_CIT0046","doi-asserted-by":"crossref","first-page":"13962","DOI":"10.18632\/oncotarget.3920","article-title":"AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1\/4E-BP1 axis","volume":"6","author":"Mi","year":"2015","journal-title":"Oncotarget."},{"issue":"2","key":"2022090114005398800_CIT0047","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/neuonc\/noy154","article-title":"Sex difference of mutation clonality in diffuse glioma evolution","volume":"21","author":"Zhang","year":"2019","journal-title":"Neuro-Oncol"},{"issue":"8","key":"2022090114005398800_CIT0048","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/labinvest.2011.75","article-title":"Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables","volume":"91","author":"Bai","year":"2011","journal-title":"Lab Investig J Tech Methods Pathol"},{"issue":"3","key":"2022090114005398800_CIT0049","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/labinvest.2014.139","article-title":"Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time","volume":"95","author":"Vassilakopoulou","year":"2015","journal-title":"Lab Investig J Tech Methods Pathol"},{"issue":"4","key":"2022090114005398800_CIT0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/labinvest.2014.7","article-title":"A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue","volume":"94","author":"Neumeister","year":"2014","journal-title":"Lab Investig J Tech Methods Pathol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac064\/43391461\/noac064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/9\/1471\/45639200\/noac064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/9\/1471\/45639200\/noac064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T15:02:57Z","timestamp":1662044577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/24\/9\/1471\/6548389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,3,14]]},"published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac064","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,3,14]]}}}